Oxeia Biopharmaceuticals, founded to address the unmet medical needs in treating mild traumatic brain injury (mTBI), focuses on developing innovative therapeutics for concussions and related neuro-metabolic dysfunctions. The company's core mission is to improve the quality of life for patients suffering from these conditions through advanced drug therapies. Their flagship product, OXE103, is a clinical-stage drug that began Phase 2 trials in fall 2020, aiming to provide effective treatment options where currently few exist.
Notable individuals affiliated with Oxeia Biopharmaceuticals include researchers from KU Medical Center who are testing the efficacy of OXE103. The company has garnered attention for its promising early results in improving concussion symptoms and overall quality of life for patients. With its pioneering approach and significant strides in clinical trials, Oxeia Biopharmaceuticals is making a substantial impact in the field of neuro-metabolic dysfunction and concussion treatment.
